Massachusetts -based Scientists have been touting using mRNA as medicine to tackle many hard-to-treat diseases, from cancer to infections to heart and kidney disorders. biotech Modena 's shares fell by around 14 percent on 2015 of trading, despite a record-breaking $ 604.3 m initial public offering giving it a value of $ 7.32bn . The market has been made jittery by fears of a Massachusetts economic slowdown amid renewed trade tensions. However, analysts are confident messenger 's deep pipeline will allow it to shrug off the negative opening. The company is developing treatments based on Modena RNAs.
Massachusetts -based biotech Modena 's shares fell by around 14 percent on 2015 of trading, despite a record-breaking $ 604.3 m initial public offering giving it a value of $ 7.32bn . The market has been made jittery by fears of a Massachusetts economic slowdown amid renewed trade tensions. However, analysts are confident messenger 's deep pipeline will allow it to shrug off the negative opening. The company is developing treatments based on Modena RNAs.